Stock market today: S&P 500 rides Apple-led tech rally to close higher
Investing.com - Canaccord Genuity raised its price target on TransMedics Group (NASDAQ:TMDX) to $142.00 from $129.00 on Tuesday, while maintaining a Buy rating on the organ transplant technology company. According to InvestingPro data, analysts maintain a strong Buy consensus with price targets ranging from $103 to $170, and six analysts have recently revised their earnings estimates upward.
The research firm identified potential upside of approximately 6% to 10% ($8.9M-$13.9M) to its previous Q2/25 US OCS case revenue estimate of $144.9M, based on aviation trends and organ market volume analysis.
Canaccord Genuity increased its Q2/25 US OCS revenue forecast to $153.7M from $144.9M and its Q2/25 total revenue projection to $158.2M from $149.3M, compared to the consensus estimate of $146.7M prior to this update.
The firm also raised its full-year 2025 total revenue estimate to $607.2M from $585.4M, exceeding both the consensus estimate of $580.4M and TransMedics’ own guidance of $565M-$585M provided after Q1/25 earnings.
Canaccord Genuity cited TransMedics’ "moat-establishing, paradigm-shifting service model" and its ability to grow the organ transplant market through extended DBD and DCD donors as key factors supporting the company’s revenue and earnings growth potential.
In other recent news, TransMedics Group reported impressive financial results for the first quarter of 2025, with revenue reaching $143.5 million, significantly surpassing the expected $123.66 million. The company’s earnings per share (EPS) also exceeded forecasts, achieving $0.70 compared to the projected $0.26. Following these results, TransMedics raised its full-year revenue guidance to a range of $565-$585 million. Oppenheimer responded by increasing the company’s stock price target to $130, maintaining an Outperform rating, while Piper Sandler raised their target to $145, citing confidence in the company’s position despite some recent challenges. Oppenheimer noted that TransMedics’ competitive positioning remains strong despite pressure from competitors like OrganOx, which recently had an "air transport" warning removed from its device. Analysts from Piper Sandler expressed optimism about TransMedics’ potential to exceed second-quarter sales estimates, despite a noted decline in transplant volumes and flight activity in May. Both firms emphasized the company’s robust momentum and strategic initiatives as key drivers for future growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.